Concerns & Risks -- 6/10
A favorable valuation leg offset by mixed catalysts and a regulatory overhang. Novo trades at ~14x
FY2027E earnings -- roughly a 50% discount to its only true peer (Eli Lilly ~30x) on every metric. China
exposure (~6%) is under the 10% threshold with Novo gaining, not losing, share. The drags: catalysts are
genuinely mixed (a dated Sept 2026 CMD and oral-pill ramp against a guided-decline 2026 with unrepaired
guidance credibility), and the April 2026 MFN pricing deal permanently resets US GLP-1 economics even as
it removes the tariff tail.
Weight: 15%
Valuation
~14x P/E
FY2027E, vs Lilly ~30x
~50% discount
China Exposure
~6%
Under 10% threshold
Gaining share
MFN Pricing Deal
Price Reset
$350/mo DTC; tariff exemption
Known drag
2026 Trajectory
Trough
Guided sales/op profit -4% to -12% CER
Guided decline
Valuation -- Primary Metric: Forward P/E
| Metric | NVO | Peer (LLY) |
|---|---|---|
| P/E (FY2027E, primary) | ~14.2x | ~29.8x |
| P/E (FY2026E trough) | ~14.3x | ~33x |
| EV/Sales (TTM) | ~4.6x | ~13-14x |
| EV/EBITDA (TTM) | ~8.5x | ~20x+ |
~14x FY2027E earnings vs Lilly ~30x -- roughly a 50% discount on every metric.
Well below peer average, the bullish leg of the rubric. The discount is "earned" (Novo is the #2
share-loser to Lilly's tirzepatide/orforglipron and consensus models 2026 as the earnings trough)
but the absolute multiple leaves room for re-rating if the trajectory stabilizes. Valuation
provisional -- FMP-sourced (Bloomberg MCP unavailable this run).
Key catalysts
| # | Catalyst | Timing | Detail |
|---|---|---|---|
| 1 | Capital Markets Day | Sept 2026 | Near-term, dated re-rating event -- new CEO Doustdar resets midterm targets. The key catalyst to flip the management gate. |
| 2 | Wegovy oral pill ramp | 2026 | DKK 2.3B first-quarter sales; key test of whether low-price access converts to durable volume. |
| 3 | CagriSema / high-dose semaglutide | 2026-2027 | Pipeline must repair the competitive gap versus Lilly. |
| 4 | US pricing stabilization | 2026 | Adjusted sales must stop declining at CER before a growth re-rate. |
| 5 | FCF recovery | 2026 | Guide raised to DKK 36-46B; capex still ~DKK 55B. |
Regulatory / political risk
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | MFN / MFP price reset | MEDIUM | April 2026 deal cuts injectable GLP-1 DTC price to $350/mo (from $1,000-1,350); permanently lowers US economics. Management frames it as "more of a 2027 event." |
| 2 | Competitive share loss to Lilly | HIGH | Tirzepatide/orforglipron clinically superior; Novo ceding GLP-1 share on both sides of the Atlantic. Cheap multiple is a value trap if the gap widens. |
| 3 | Generic semaglutide (China) | MEDIUM | Generic entry in China ~2027 is the forward risk; China is ~6% of sales, currently gaining share. |
| 4 | Guidance credibility | HIGH | Freshly broken -- 0/4 on FY2025 promises, three cuts, CEO change. Not yet repaired. |
| 5 | Tariffs | LOW | Largely de-risked -- MFN deal secured a 3-year tariff exemption vs a threatened 100% branded-drug tariff. |
Bull case
| # | Factor | Detail |
|---|---|---|
| 1 | ~50% Discount to Lilly | ~14x FY2027E earnings for a #1/#2 GLP-1 duopolist in a secular obesity TAM. Below peer on every metric. |
| 2 | 2026 Is the Trough | Consensus models 2026 as the earnings trough with only modest 2027 recovery -- classic worse-to-better inversion setup. |
| 3 | Dated Catalysts | Oral Wegovy pill, CagriSema, and a Sept 2026 CMD with a fresh, execution-focused CEO. |
| 4 | Tariff Tail Removed | MFN deal secured a 3-year tariff exemption, converting an open-ended overhang into a known, modeled drag. |
| 5 | China Gaining Share | China at ~6% of sales, with Novo gaining (not losing) share; competition "not yet present." |
Bear case
| # | Factor | Detail |
|---|---|---|
| 1 | Value Trap Risk | Novo is the share-loser to Lilly's superior tirzepatide/orforglipron; the cheap multiple is a trap if the competitive gap widens. |
| 2 | Core Franchise Eroding | Ozempic (DKK 27.8B, down YoY) and Rybelsus eroding; the Q1 "beat" was optically inflated by a one-time DKK 26.8B 340B reversal. |
| 3 | Permanent US Price Reset | MFN/MFP permanently resets US price/unit; a structural headwind to the highest-margin geography. |
| 4 | Guided-Decline 2026 | Sales/op profit guided -4% to -12% CER; management flags "high visibility on price, low visibility on volume." |
| 5 | Credibility Not Repaired | Guidance credibility broken and unproven under the new CEO until the Sept 2026 CMD delivers. |
Score rationale
Score of 6/10 reflects a favorable valuation leg offset by mixed catalysts and a real, partially de-risked regulatory overhang.
What pulls it up: Valuation is squarely bullish — ~14x forward P/E is well below the Lilly peer (~30x) on every metric (+). China exposure (~6%) is under the 10% threshold with Novo gaining, not losing, share (+). MFN deal removes the tariff tail (+).
What caps it: Catalysts are genuinely mixed — a dated Sept 2026 CMD and oral-pill ramp against a guided-decline 2026 with unrepaired guidance credibility (-). The April 2026 MFN pricing deal permanently lowers US GLP-1 economics even as it removes the tariff tail (-). The still-negative 2026 trajectory and the #2-and-losing-share competitive position keep it below a clean high score.
Net: below-peer valuation and sub-10% China pull it up, but the lingering MFN/MFP price reset and the still-negative 2026 trajectory cap it at 6/10 — a quality franchise at a cheap multiple, with real but mixed, dated catalysts.
Data sourced from Daloopa (company_id: 50204). Valuation multiples provisional -- FMP-sourced (Bloomberg MCP unavailable this run). Reporting currency DKK.